| Dr Johan Sebastian Urena Hernandez, MD | |
|
1661 S Main St, Harrisonburg, VA 22801-2728 | |
| (540) 564-7100 | |
| (757) 579-8634 |
| Full Name | Dr Johan Sebastian Urena Hernandez |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 21 Years |
| Location | 1661 S Main St, Harrisonburg, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083851851 | NPI | - | NPPES |
| 1083851851 | Medicaid | VA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 0101246924 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sentara Home Care Services-virginia Beach | Chesapeake, VA | Home health agency |
| Sentara Princess Anne Hospital | Virginia beach, VA | Hospital |
| Sentara Virginia Beach General Hospital | Virginia beach, VA | Hospital |
| Sentara Leigh Hospital | Norfolk, VA | Hospital |
| Sentara Norfolk General Hospital | Norfolk, VA | Hospital |
| Sentara Obici Hospital | Suffolk, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sentara Medical Group | 8921903923 | 1058 |
News Archive
Making tumor cells glow: Medical physicists at Martin Luther University Halle-Wittenberg (MLU) have developed a new method that can generate detailed three-dimensional images of the body's interior.
Anacor Pharmaceuticals, the University of California San Francisco (UCSF) Sandler Center and the Lindsley F. Kimball Research Institute (LFKRI) of the New York Blood Center (NYBC) today announced the establishment of a research and development collaboration to discover new drug therapies for the treatment of river blindness (onchocerciasis), a parasitic disease that is the second leading cause of infectious blindness worldwide, and is most prevalent in Africa.
"One of the most urgent global public health problems is the increasing capability of bacteria to resist antibiotic drugs," a Washington Post editorial states.
Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.
Having received clearance under Section 510(k) from the U.S. Food and Drug Administration, Spacelabs Healthcare is adding the qube patient monitor to its Art of Monitoring portfolio. Inspired by the revolutionary style of the company's XPREZZON patient monitor, qube breaks with tradition to offer a fresh, new perspective in compact monitoring.
› Verified 3 days ago
| Entity Name | Sentara Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265485270 PECOS PAC ID: 8921903923 Enrollment ID: O20031203000466 |
News Archive
Making tumor cells glow: Medical physicists at Martin Luther University Halle-Wittenberg (MLU) have developed a new method that can generate detailed three-dimensional images of the body's interior.
Anacor Pharmaceuticals, the University of California San Francisco (UCSF) Sandler Center and the Lindsley F. Kimball Research Institute (LFKRI) of the New York Blood Center (NYBC) today announced the establishment of a research and development collaboration to discover new drug therapies for the treatment of river blindness (onchocerciasis), a parasitic disease that is the second leading cause of infectious blindness worldwide, and is most prevalent in Africa.
"One of the most urgent global public health problems is the increasing capability of bacteria to resist antibiotic drugs," a Washington Post editorial states.
Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.
Having received clearance under Section 510(k) from the U.S. Food and Drug Administration, Spacelabs Healthcare is adding the qube patient monitor to its Art of Monitoring portfolio. Inspired by the revolutionary style of the company's XPREZZON patient monitor, qube breaks with tradition to offer a fresh, new perspective in compact monitoring.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Johan Sebastian Urena Hernandez, MD Po Box 1430, Harrisonburg, VA 22803-1430 Ph: (540) 564-5644 | Dr Johan Sebastian Urena Hernandez, MD 1661 S Main St, Harrisonburg, VA 22801-2728 Ph: (540) 564-7100 |
News Archive
Making tumor cells glow: Medical physicists at Martin Luther University Halle-Wittenberg (MLU) have developed a new method that can generate detailed three-dimensional images of the body's interior.
Anacor Pharmaceuticals, the University of California San Francisco (UCSF) Sandler Center and the Lindsley F. Kimball Research Institute (LFKRI) of the New York Blood Center (NYBC) today announced the establishment of a research and development collaboration to discover new drug therapies for the treatment of river blindness (onchocerciasis), a parasitic disease that is the second leading cause of infectious blindness worldwide, and is most prevalent in Africa.
"One of the most urgent global public health problems is the increasing capability of bacteria to resist antibiotic drugs," a Washington Post editorial states.
Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.
Having received clearance under Section 510(k) from the U.S. Food and Drug Administration, Spacelabs Healthcare is adding the qube patient monitor to its Art of Monitoring portfolio. Inspired by the revolutionary style of the company's XPREZZON patient monitor, qube breaks with tradition to offer a fresh, new perspective in compact monitoring.
› Verified 3 days ago
Walid Samih Alami, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2006 Campus Health Dr, Ste. 300, Harrisonburg, VA 22801 Phone: 540-689-7400 | |
Dr. Sachin Sharma, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2010 Health Campus Dr, Harrisonburg, VA 22801 Phone: 540-689-1110 Fax: 540-689-1119 | |
Dr. Tracey Robinson, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2006 Health Campus Dr, Harrisonburg, VA 22801 Phone: 540-689-5700 Fax: 540-689-5701 | |
Dr. Timothy C. Landes, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1871 Evelyn Byrd Ave, Harrisonburg, VA 22801 Phone: 540-564-5800 Fax: 540-564-5801 | |
Thomas Anthony Bahleda, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 235 Cantrell Ave, Harrisonburg, VA 22801 Phone: 540-564-7364 Fax: 540-564-7365 | |
Dr. Ilija Steven Rakaric, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 1920 Medical Ave, Ste F, Harrisonburg, VA 22801 Phone: 540-908-3095 Fax: 540-908-3085 |